Amikacin is a potent, broad-spectrum aminoglycoside that is often used with ß-lactams for severe gram-negative infections. Despite its widespread uses, a substantial increase in antimicrobial resistance over the years has not been observed 1, 2 . Pharmacokinetic (PK) and pharmacodynamic (PD) properties of antibiotics are vital to determine optimal dosing regimens in critically ill patients 3 because considerable interactions between the pathophysiological changes of critical illness and the PK/PD properties of antibiotics can occur 4, 5 . For example, amikacin and other aminoglycosides all have an increased volume of distribution (Vd) in patients with severe critical illness, and this reduces the peak or maximum plasma concentrations of the antibiotic when a standard loading dose is used [6] [7] [8] [9] . As the data on PK properties of aminoglycosides in patients with severe sepsis are limited, most clinicians rely on therapeutic drug monitoring (TDM) to guide the dosing of aminoglycosides in critically ill patients.
Aminoglycosides, including amikacin, exhibit concentration-dependent killing characteristics, and the rate and extent of bactericidal effects increases with plasma concentration. As such, achieving a high peak plasma concentration and an adequate area under the concentration-time curve (AUC) are pivotal in optimising the therapeutic effect of amikacin. In patients with a high Vd or drug clearance, the AUC is thus useful in titrating the dose of amikacin accordingly 10, 11 . Accurate determination of the AUC for amikacin (AUC 0-24 ) requires, however, multiple blood samples during a 24-hour period which is very labour intensive. Whether a more limited sampling strategy (LSS) can reliably reflect the AUC 0-24 of amikacin in critically ill patients remains uncertain. We SUMMARy Aminoglycosides are a class of antibiotics that are commonly used in the treatment of gram-negative pathogens in the critically ill population. Unfortunately, dosing of these aminoglycosides in critically ill patients is difficult due to their altered pharmacokinetics in the critically ill and narrow therapeutic index. In this study, we evaluated whether a limited sampling strategy can be used to predict the area under the concentration (AUC) curve of amikacin concentrations over a 24-hour period after a single dose of intravenous amikacin (25 mg/kg). This open-labelled, non-comparative prospective study recruited 20 adult critically ill trauma patients with a diagnosis of hospital-acquired infection. We assessed the best estimate of plasma amikacin concentrations over a 24-hour period by multiple stepwise regression, using nine blood samples during this study period as the gold standard. Using a jackknife procedure, the AUC of amikacin over a 24-hour period was estimated by choosing a combination of the amikacin concentrations measured at different time-points. overall, the mean prediction error of all models was not statistically different from zero (P >0.05). Based on bias and imprecision, all models gave good estimate of AUC of amikacin over a 24-hour period, but a two-point sampling strategy at 1.5 and 6 hours post-dose appeared to offer the best compromise between accuracy and cost-effectiveness in optimising the dosing of amikacin in critically ill patients. 
MATeRIALS AnD MeThoDS
After obtaining hospital ethics committee approval (89-04-33-11814) and written informed consent from the patients and/or their legal guardian, 20 critically ill patients with hospital-acquired infection requiring the use of amikacin over a ten-month period were enrolled in this study. Patients with burn injury or cystic fibrosis (because of an increased Vd), age <18 years old, pregnancy, neuromuscular disease, body mass index >40 kg/m 2 , amikacin treatment within two weeks, chronic renal failure requiring dialysis and known allergy to aminoglycosides were excluded. We studied the PK properties of amikacin in the first 24 hours of amikacin treatment, and all study patients were only studied once in this study. The standard initial treatment protocol for severe gramnegative infection was a loading dose of 25 mg/kg of amikacin, administered over 60 minutes, in addition to a broad-spectrum ß-lactam (ceftazidime, cefepime, piperacillin-tazobactam or meropenem) given by two separate intravenous lines. Severity of acute illness and organ dysfunction were characterised by the Acute Physiology and Chronic health evaluation (APAChe) II score 12 and Sequential organ Failure Assessment score 13 , respectively.
Blood sampling and drug assay
A total of nine venous blood samples for drug assays were obtained at 15, 30, 60 and 90 minutes, as well as 4, 6, 12, 18 and 24 hours after the administration of amikacin. A 5 ml plain collection tube without anticoagulant was used for all blood samples. The sample was first centrifuged (ten minutes, 15,000 rpm) and then the serum was stored at -80°C for analysis later. At the end of the study, serum concentrations of amikacin were quantified in replicates by means of fluorescence polarisation immunoassay using the TDx ® analyser (Abbott Gmbh & Co., Wiesbaden, Germany). According to the manufacturer, the lower limit of quantification of this assay was 0.6 mg/l and the analytical precision was 3.18%, 2.62% and 2.50% for low (5 mg/l), medium (15 mg/l) and high (30 mg/l) concentrations, respectively.
PK and statistical analysis
The full amikacin AUC 0-24 model and PK profile was calculated from the amikacin plasma concentrations measured at nine different time-points using the linear trapezoidal method. To determine the time-points that best fitted the amikacin AUC 0-24 , a multiple stepwise regression analysis was used. The Pearson r procedure was used to calculate correlation coefficients and the jackknife procedure was used to validate the regression analysis 14 . SPSS for Windows (version 11.5, IBM, Armonk, ny, USA) was used for all statistical analyses and P values less than 0.05 were considered as significant in this study.
Limited sampling strategy
To estimate whether the full PK profile or AUC 0-24 model of amikacin can be predicted by using a smaller number of blood samples, we modelled the precision and accuracy of different LSS using a variety of combinations of different sampling time-points compared to the full amikacin AUC 0-24 model. Data analysis was performed using the following approach:
Step 1: Multiple linear regression was used to estimate the AUC and each time-point of amikacin concentrations that best fitted the amikacin AUC 0-24 . The models with P <0.05 for any sampling timepoints and a high correlation coefficient were selected (r² >0.75). These analyses produced equations in the form of AUC=α1C1+αnCn+ß, where n is the number of samples (n >3) and α and ß were the coefficients.
Step 2: Internal validation was then performed by means of a jackknife procedure 14 . In the absence of dependent and independent variables of n patients, a model equation was derived from n-1 patients to predict AUCs for n patients. We had 20 patients in our study and the AUC was predicted for each of 20 patients using the other 19 patients' data. At this step, the acceptable predicted AUCs were those LSS with P <0.05.
Step 3: The prediction error of the LSS, predicted AUC-measured AUC, for each patient was calculated. Absolute bias was measured by the mean prediction error (MPe) and absolute imprecision was measured by the mean square prediction error (MSPe) for each LSS model. The model that MPe was not statistically different from zero (one sample t-test, P >0.05) with the lowest MSPe gave the best performance to estimate the abbreviated AUC.
ReSULTS

Study population
A total of 20 critically ill adult patients with the diagnosis of hospital-acquired infection requiring amikacin treatment were enrolled in this study over a ten-month period. The characteristics of these patients are described in Table 1 .
Concentration-time profile
The mean value (± standard deviation) of amikacin plasma concentration-time profiles of 20 patients are shown in Figure 1 . After a loading dose of 25 mg/ kg amikacin was given, the full amikacin PK model showed that the mean AUC 0-24 was 392+124 mg/h/l.
Limited sampling strategy
Using a single time-point at six hours post-dose (Model 1: r²=0.447) had the lowest correlation with the full amikacin AUC 0-24 model. Using two timepoints at 1.5 and 6 hours post-dose improved the correlation with the full amikacin AUC 0-24 model substantially (Model 2: r 2 =0.816), and using three amikacin concentrations at 1.5, 4 and 6 hours postdose had the highest correlation with the full amikacin AUC 0-24 model that used nine time-points (Model 3: r²=0.993). The equations of the three LSS models to estimate amikacin AUC 0-24 are shown in Table 2 .
Using a jackknife procedure, the MPe of all models were not statistically different from zero (one sample t-test P >0.05), with the confidence interval including zero. Accordingly, all three models provided unbiased estimations of the full amikacin AUC 0-24 model (Table 3 ). Internal validation showed that Model 3, using a three-point sampling strategy at 1.5, 4 and 6 hours post-dose, had the best performance in estimating the full amikacin AUC 0-24 model (MSPe=0.02112) ( Table 3) . The imprecision and bias of all three equations are described in Figure 2 , in which the observed amikacin AUC 0-24 and predicted amikacin AUC 0-24 of each individual patient are compared.
DISCUSSIon
our results showed that the AUC 0-24 profile of amikacin can be reliably estimated by using plasma amikacin concentrations at three time-points (1.5, 4 and 6 hours) in critically ill patients with nosocomial sepsis requiring once daily dosing of amikacin. This result has some clinical significance and requires further discussion.
First, amikacin has a narrow therapeutic range. Therefore, achieving an optimal plasma concentration profile of amikacin is essential in optimising its kill characteristic as well avoiding nephrotoxicity 10, 11, 15 . Traditionally, peak and trough amikacin concentrations have been used to guide drug dosing. This approach appears, however, inefficient with the once-daily dosing strategy 16 , especially in critically ill patients when an increased Vd and clearance are often observed 4, 5 . It is important to note that both the rate and extent of the bactericidal effect of amikacin have a strong relation to maximum or peak concentration as well as the AUC over time due to its concentration-dependent bactericidal activity, and the post-antibiotic effect of amikacin is also related to the peak concentration and AUC. Furthermore, the AUC of amikacin is a measure of total drug exposure and has a significant association with the risk of renal and ototoxicity of aminoglycosides 15 , making these two PK parameters important monitoring targets 11 . The use of amikacin AUC 0-24 is, however, limited at a practical level by the labour-intensive nature of multiple blood samplings. our results showed that a two or three time-point LSS can reflect the amikacin AUC 0-24 profile, making this strategy of profiling amikacin in critically ill patients much more practical and appealing. This result was largely consistent with a recent Bayesian population-based amikacin PK model in critically ill patients 17 . In this study, 25 mg/kg amikacin was administered once daily and the authors proposed that two sampling time-points at one and six hours after the drug infusion are the most optimal sampling times for Bayesian estimation of amikacin PK properties 17 . Although LSS to individualise treatment dosage of different antibiotics such as meropenem 18 , ciprofloxacin 19 and vancomycin 20 has been reported, as far as we know there is no clinical study that has developed LSS PK models for amikacin in critically ill patients with sepsis.
Second, although the three time-point LSS was most accurate in estimating the full amikacin AUC 0-24 model, it can still be argued that two time-points at 1.5 and 6 hours post-dose may be adequate and possibly more cost-effective at a practical level. Measuring amikacin plasma concentration only at a single time-point, at six hours post-dose, substantially reduced its reliability in estimating the full amikacin AUC 0-24 profile and this practice is thus not supported by our results. our results suggested that the traditional practice of measuring only the peak and trough aminoglycoside concentrations is inadequate. Similar to the results of other studies 11, 17 , the most important sampling time which reflects the AUC 0-24 profile is the plasma concentration six hours after the administration of aminoglycosides and not the peak concentration.
This study has some limitations. First, the PK profile of amikacin was evaluated only during the first 24 hours of administration and thus we cannot confirm whether the proposed LSS still works for patients who have received multiple doses of amikacin. Second, inactivation of aminoglycosides can occur when they are administrated simultaneously with some ß-lactams. however, amikacin is less affected by this phenomenon, and frozen samples, as in this study, may further minimise any drug inactivation 21 . Third, all our study patients had relatively normal renal function, and hence our results cannot be extrapolated to critically ill patients who have significant renal impairment or are on dialysis.
In conclusion, our results suggested that both two time-point and three time-point amikacin LSS give good estimates of the full nine time-point amikacin AUC 0-24 model in critically ill patients with sepsis and normal renal function. Sampling at 1.5 and 6 hours post-dose has an acceptable precision in estimating the amikacin AUC 0-24 profile and is more practical in critically ill patients. Further research is needed to assess whether our results can be generalised to noncritically ill patients. 
